专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明公开

EP2678431A4 OLIGONUCLEOTIDE INHIBITORS WITH CHIMERIC BACKBONE AND 2-AMINO-2'-DEOXYADENOSINE 审中-公开
标题翻译：用钥匙链嵌合和2-氨基-2'-脱氧腺苷OLIGONUKLEOTIDHEMMER
公开(公告)号：EP2678431A4
公开(公告)日：2015-07-15
申请号：EP12749352
申请日：2012-02-23
申请人： PHARMAXIS LTD
发明人： SEGUIN ROSANNE , FERRARI NICOLAY
IPC分类号： C12N15/113 , A61K31/7125 , A61P11/00 , A61P29/00 , C07H21/00 , C12N15/19 , C12N15/55
CPC分类号： C12N15/1137 , A61K31/7125 , C07H21/00 , C12N15/111 , C12N15/1136 , C12N15/1138 , C12N2310/11 , C12N2310/315 , C12N2310/333 , C12N2310/343 , C12Y301/04017

3. 发明公开

EP1192261A1 22025, A NOVEL HUMAN CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 有权
标题翻译： 22025，新的人力CYCLICAL核苷酸磷酸二酯酶
公开(公告)号：EP1192261A1
公开(公告)日：2002-04-03
申请号：EP00941369.1
申请日：2000-06-12
申请人： Millennium Pharmaceuticals, Inc.
发明人： ROBISON, Keith, E. , KAPELLER-LIBERMANN, Rosana , WHITE, David
IPC分类号： C12N15/55 , C12N9/16 , C12Q1/68 , C12Q1/44 , A61K38/46 , C07K16/40
CPC分类号： C12Y301/04017 , A61K38/00 , C12N9/16
摘要： The present invention relates to a newly identified human cyclic nucleotide phosphodiesterase belonging to the superfamily of mammalian phosphodiesterases. The invention also relates to polynucleotides encoding the phosphodiesterase. The invention further relates to methods using the phosphodiesterase polypeptides and polynucleotides as a target for diagnosis and treatment in phosphodiesterase-mediated or -related disorders. The invention further relates to drug-screening methods using the phosphodiesterase polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the phosphodiesterase polypeptides and polynucleotides. The invention further relates to procedures for producing the phosphodiesterase polypeptides and polynucleotides.

5. 发明授权

EP2430190B1 PHOSPHODIESTERASE 4D7 AS MARKER FOR MALIGNANT, HORMONE-SENSITIVE PROSTATE CANCER 有权转让
公开(公告)号：EP2430190B1
公开(公告)日：2018-11-21
申请号：EP10726250.3
申请日：2010-05-11
申请人： Koninklijke Philips N.V. , University Court Of The University Of Glasgow
发明人： HOFFMANN, Ralf , HOUSLAY, Miles, D. , HENDERSON, David, J. P.
IPC分类号： C12N15/115 , C12N15/113 , C12Q1/68 , G01N33/574 , C12N9/16 , C12Q1/44 , C12N15/11
CPC分类号： C12Q1/6886 , C12N9/16 , C12N15/1137 , C12N15/115 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12Q1/44 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Y301/04017 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive prostate cancer.

6. 发明公开

EP1865978A2 NEW NEURONAL PAIN PATHWAY 审中-公开
标题翻译：新的神经疼痛TRAIN
公开(公告)号：EP1865978A2
公开(公告)日：2007-12-19
申请号：EP06748487.3
申请日：2006-03-21
申请人： The Trustees of Columbia University in the City of New York
发明人： AMBRON, Richard , SUNG, Ying-Ju , LANDRY, Donald, W. , DENG, Shi-Zian
IPC分类号： A61K38/10 , A61K38/08 , A61K38/05 , A61K9/70
CPC分类号： A61K38/06 , A61K9/0014 , A61K9/7023 , A61K31/352 , A61K31/4422 , A61K31/55 , A61K38/02 , A61K38/07 , A61K38/465 , A61K47/48246 , A61K47/64 , C12N9/1205 , C12Y301/04017
摘要： The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G ("PKG"), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.

7. 发明授权

EP2601964B1 Balanol compounds for use in treating pain 有权
公开(公告)号：EP2601964B1
公开(公告)日：2018-07-25
申请号：EP12177074.7
申请日：2006-03-21
申请人： The Trustees of Columbia University in the City of New York
发明人： Ambron, Richard , Sung, Ying-Ju , Landry, Donald W , Deng, Shi-Zian
IPC分类号： A61K38/06 , A61K38/07 , A61K38/08 , A61K38/10 , A61K31/55 , A61K38/04 , A61K38/16 , A61K38/46 , A61K9/70 , A61K38/02 , A61K9/00 , A61K31/352 , A61K31/4422 , A61K47/64 , C12N9/12 , A61P25/00
CPC分类号： A61K38/06 , A61K9/0014 , A61K9/7023 , A61K31/352 , A61K31/4422 , A61K31/55 , A61K38/02 , A61K38/07 , A61K38/465 , A61K47/64 , C12N9/1205 , C12Y301/04017
摘要： The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G ("PKG"), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.

8. 发明公开

EP2836240A4 COMPOSITIONS AND METHODS FOR TREATING OTITIS MEDIA AND OTHER CONDITIONS WITH INHIBITORS OF CYLD 审中-公开
标题翻译：组合物和方法用于治疗中耳发炎等疾病的CYLD抑制剂
公开(公告)号：EP2836240A4
公开(公告)日：2016-05-11
申请号：EP13775519
申请日：2013-04-09
申请人： UNIV GEORGIA STATE RES FOUND
发明人： LI JIAN-DONG
IPC分类号： A61K48/00 , A61K31/40 , A61K31/44 , A61P29/00
CPC分类号： C12N15/1137 , A61K31/277 , A61K31/4015 , A61K31/4174 , A61K31/44 , A61K31/685 , A61K31/7064 , A61K31/713 , C12N2310/11 , C12N2310/14 , C12N2310/141 , C12Q1/68 , C12Y301/04017 , C12Y304/19012
摘要： The present invention is based, in part, on our studies of molecular pathways that include the deubiquitinase CYLD. Accordingly, the present invention features, inter alia, nucleic acid constructs that express CYLD or a biologically active variant thereof (e.g., a variant including the catalytic domain), nucleic acids that inhibit the expression of a negative regulator of CYLD (e.g., PDE4B or LNK2), nucleic acids that modulate the expression of downstream CYLD targets (e.g., Akt, by inhibiting or promoting the expression of the downstream target), compositions including one or more of these types of constructs (e.g., pharmaceutical compositions), kits including one or more of the compositions described herein and instructions for use, screening methods to identify therapeutic agents {e.g., anti-inflammatory agents) that upregulate CYLD, downregulate a negative regulatory of CYLD, or modulate (e.g., inhibit) a downstream CYLD target (e.g., Akt), and various methods of treatment including the administration of the nucleic acids described above, protein biotherapeutics, and/or small molecules, alone or in combination, to address cancer, inflammation, and fibrosis. The compositions described herein can be used in the preparation of a medicament (e.g., used in the preparation of a medicament to treat cancer, inflammation, fibrosis, or one or more of the more specific conditions described herein).
摘要翻译：本发明是基于在某种程度上，我们的分子途径的研究没有包括去泛素化酶CYLD。因此，本发明的特征在于，除其他外，核酸构建体没有明示CYLD或其生物活性变体（例如，变体包括催化结构域），核酸确实抑制CYLD的负调节剂（例如，PDE4B的表达或 LNK2），核酸没有调制的下游CYLD目标（表达例如，AKT，通过抑制或促销婷下游靶标的表达），组合物，包括一种或多种本文类型构建体（包括一个例如，药物组合物）的试剂盒的或多种的组合物中和使用说明描述，筛选方法以鉴定治疗剂{例如，抗炎剂）也上调CYLD，下调负调节CYLD的，或调节（例如，抑制）的下游CYLD目标（例如，动作），并包括的上述核酸，蛋白质的生物治疗药物给药治疗的各种方法和/或小分子，单独或在组合，以解决癌症，炎症和纤维化。在可以在药物的制备中使用所述的组合物（例如，在药物的制备中用于治疗癌症，炎症，纤维化，或一个或多个描述的更具体的病症）。

9. 发明公开

EP2430190A1 PHOSPHODIESTERASE 4D7 AS MARKER FOR MALIGNANT, HORMONE-SENSITIVE PROSTATE CANCER 有权转让
标题翻译： PHOSPHODIESTERASE 4D7 ALS KREBSMARKER
公开(公告)号：EP2430190A1
公开(公告)日：2012-03-21
申请号：EP10726250.3
申请日：2010-05-11
申请人： Koninklijke Philips Electronics N.V. , University Court Of The University Of Glasgow
发明人： HOFFMANN, Ralf , HOUSLAY, Miles, D. , HENDERSON, David, J. P.
IPC分类号： C12Q1/68 , G01N33/574 , C12N9/16 , C12Q1/44 , C12N15/11
CPC分类号： C12Q1/6886 , C12N9/16 , C12N15/1137 , C12N15/115 , C12N2310/11 , C12N2310/14 , C12N2310/16 , C12Q1/44 , C12Q2600/106 , C12Q2600/112 , C12Q2600/158 , C12Y301/04017 , G01N33/57434 , G01N2800/52
摘要： The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive prostate cancer.
摘要翻译：本发明涉及用作恶性，激素敏感性前列腺癌的标志物的磷酸二酯酶4D7（PDE4D7），其中当将恶性，激素敏感性前列腺癌组织中的表达与恶性，激素敏感性前列腺癌组织中的表达比较时，标志物的表达增加正常组织或良性前列腺肿瘤组织，以及使用PDE4D7作为恶性，激素敏感性前列腺癌的诊断标志物。本发明还涉及用于诊断，检测，监测或预测恶性，激素敏感性前列腺癌的组合物，相应的检测方法，允许区分良性和恶性激素敏感性前列腺癌的方法和数据采集方法，以及相应的免疫测定。本发明还涉及鉴定个体对恶性，激素敏感性前列腺癌的资格的方法以及用这种前列腺癌分层个体的免疫测定法。本发明进一步设想药物组合物及其用于治疗恶性，激素敏感性前列腺癌的用途。

10. 发明公开

EP2152870A2 RNA INTERFERENCE MEDIATED INHIBITION OF CYCLIC NUCLEOTIDE TYPE 4 PHOSPHODIESTERASE (PDE4B) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA) 审中-公开
标题翻译：使用新浪环核苷酸磷酸二酯酶4型（PDE4B）的基因表达的RNA干扰介导的抑制（短干扰核酸）
公开(公告)号：EP2152870A2
公开(公告)日：2010-02-17
申请号：EP08747584.4
申请日：2008-05-02
申请人： Sirna Therapeutics Inc.
发明人： STRAPPS, Walter , JADHAV, Vasant , VARGEESE, Chandra , RICHARDS, Ivan
IPC分类号： C12N15/09
CPC分类号： C12N15/1137 , C12N2310/14 , C12Y301/04017
摘要： The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression and/or activity, including PDE4B1, PDE4B2, and PDE4B3 gene expression and/or activity. The present invention is also directed to compounds, compositions, and methods relating to traits, diseases and conditions that respond to the modulation of expression and/or activity of genes involved in cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression pathways or other cellular processes that mediate the maintenance or development of such traits, diseases and conditions, including but not limited to IL-6, IL-I, IL-8, IL- 15, TNF-alpha and matrix metalloproteinases (MMPs), such as MMP-I, MMP -2, MMP-3, MMP-9 and MMP- 12. Specifically, the invention relates to double stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA), and multifunctional siNA molecules capable of mediating RNA interference (RNAi) against cyclic nucleotide type 4 phosphodiesterase (PDE4B) gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. The present invention also relates to small nucleic acid molecules, such as siNA, siRNA, antisense and others that can inhibit the function of endogenous RNA molecules or RNAi pathway components (RNAi inhibitors), such as endogenous micro-RNA (miRNA) (e.g, miRNA inhibitors) or endogenous short interfering RNA (siRNA), (e.g., siRNA inhibitors) or that can inhibit the function of RISC (e.g., RISC inhibitors), to modulate PDE4B gene expression by interfering with the regulatory function of such endogenous RNAs or proteins associated with such endogenous RNAs (e.g., RISC) including cocktails of such small nucleic acid molecules and lipid nanoparticle (LNP) formulations of such small nucleic acid molecules. Such small nucleic acid molecules are useful, for example, in providing compositions to prevent, inhibit, or reduce inflammatory, respiratory, and autoimmune diseases, traits, and conditions, and/or other disease states associated with PDE4B gene expression or activity in a subject or organism.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式